國家衛生研究院 NHRI:Items for Author

Year

Loading year class tree, please wait....

Items for Author "Lee, KW"

Return to Browse by Author

Showing 22 items.

Collection	Date	Title	Relation
[葛應欽(2003-2009)] 期刊論文	2005-12-10	Different impact from betel quid, alcohol and cigarette: Risk factors for pharyngeal and laryngeal cancer	-
[葛應欽(2003-2009)] 期刊論文	2006-04	Interaction between cigarette, alcohol and betel nut use on esophageal cancer risk in Taiwan	-
[張俊彥] 期刊論文	2010-04	Arecoline arrests cells at prometaphase by deregulating mitotic spindle assembly and spindle assembly checkpoint: Implication for carcinogenesis	-
[徐善慧] 期刊論文	2011	Primary adipose-derived stem cells enriched by growth factor treatment improves cell adaptability toward cardiovascular differentiation in a rodent model of acute myocardial infarction	-
[劉淦光(2006-2014)] 期刊論文	2013-04	Changes in the genome-wide localization pattern of Sir3 in Saccharomyces cerevisiae during different growth stages	-
[劉淦光(2006-2014)] 期刊論文	2013-09-27	Structure of native oligomeric Sprouty2 by electron microscopy and its property of electroconductivity	-
[其他] 期刊論文	2015-08	Analysis of differentially expressed novel post-translational modifications of plasma apolipoprotein E in Taiwanese females with breast cancer	-
[陳立宗] 會議論文/會議摘要	2017-02	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial	-
[陳立宗] 會議論文/會議摘要	2017-09	Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)	-
[陳立宗] 會議論文/會議摘要	2017-09	A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)	-
[陳立宗] 期刊論文	2017-12	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial	-
[陳立宗] 期刊論文	2019-02	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4)	-
[陳立宗] 會議論文/會議摘要	2019-02	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2	-
[陳立宗] 期刊論文	2020-01	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer	-
[陳立宗] 會議論文/會議摘要	2020-02	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data	-
[陳立宗] 期刊論文	2020-05	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data	-
[陳立宗] 會議論文/會議摘要	2020-09	Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study	-
[陳立宗] 期刊論文	2021-07	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab	-
[陳立宗] 期刊論文	2022-01	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study	-
[陳立宗] 期刊論文	2022-02	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr	-
[陳立宗] 期刊論文	2024-08-20	Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri	-
[譚澤華] 期刊論文	2024-11-08	Endosomes serve as signaling platforms for RIG-I ubiquitination and activation	-

Loading...

Category

Year

Items for Author "Lee, KW"